Unmet needs and new models for future trials in autoimmune hepatitis.

[1]  A. Lohse,et al.  Access to care in rare liver diseases: New challenges and new opportunities. , 2017, Journal of hepatology.

[2]  M. Färkkilä,et al.  Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis , 2017, Scandinavian journal of gastroenterology.

[3]  N. Alkhouri,et al.  The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience , 2017, Scandinavian journal of gastroenterology.

[4]  A. Lohse,et al.  Efficacy and Limitations of Budesonide as a Second‐Line Treatment for Patients With Autoimmune Hepatitis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  S. Kakar,et al.  Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria , 2017, Modern Pathology.

[6]  A. Kahraman,et al.  Performance and Utility of Transient Elastography and Non-Invasive Markers of Liver Fiibrosis in Patients with Autoimmune Hepatitis: A Single Centre Experience , 2016, Hepatitis monthly.

[7]  A. Quaas,et al.  Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. , 2016, Journal of hepatology.

[8]  J. Hodson,et al.  Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy , 2016, Scandinavian journal of gastroenterology.

[9]  A. Lohse,et al.  Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  M. Karajeh,et al.  Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis , 2015, The American Journal of Gastroenterology.

[11]  A. Lohse,et al.  Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. , 2015, Journal of hepatology.

[12]  D. Jothimani,et al.  Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. , 2014, Journal of clinical and experimental hepatology.

[13]  B. Löwe,et al.  Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. , 2014, Journal of hepatology.

[14]  P. Trivedi,et al.  Treatment of autoimmune liver disease: current and future therapeutic options , 2013, Therapeutic advances in chronic disease.

[15]  S. Abbey,et al.  Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. , 2012, Journal of hepatology.

[16]  M. Heneghan,et al.  British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis , 2011, Gut.

[17]  M. Campbell,et al.  Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. , 2011, Gastroenterology.

[18]  S. Hellweg,et al.  Treatment response in patients with autoimmune hepatitis , 2010, Hepatology.

[19]  M. Lenzi,et al.  Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis , 2010, Hepatology.

[20]  M. Manns,et al.  Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. , 2010, Gastroenterology.

[21]  K. Brown,et al.  Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[22]  M. Manns,et al.  Diagnosis and management of autoimmune hepatitis , 2010, Hepatology.

[23]  P. Galle,et al.  Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis? , 2008, The American Journal of Gastroenterology.

[24]  Stefan Lüth,et al.  Serologic Markers Compared With Liver Biopsy for Monitoring Disease Activity in Autoimmune Hepatitis , 2008, Journal of clinical gastroenterology.

[25]  K. Boberg,et al.  Simplified criteria for the diagnosis of autoimmune hepatitis , 2008, Hepatology.

[26]  A. Bergquist,et al.  Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study , 2008, Scandinavian journal of gastroenterology.

[27]  A. Montano‐Loza,et al.  Improving the End Point of Corticosteroid Therapy in Type 1 Autoimmune Hepatitis to Reduce the Frequency of Relapse , 2007, The American Journal of Gastroenterology.

[28]  B. Portmann,et al.  Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. , 2006, Journal of hepatology.

[29]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[30]  S. Pocock,et al.  Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. , 1980, Gut.

[31]  W. Summerskill,et al.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. , 1975, Gut.

[32]  R. Stern,et al.  Controlled trial of prednisone and azathioprine in active chronic hepatitis. , 1973, Lancet.

[33]  L. Elveback,et al.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. , 1972, Gastroenterology.

[34]  S. Sherlock,et al.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. , 1971, The Quarterly journal of medicine.

[35]  D. Jones,et al.  UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis , 2016 .

[36]  J. Drenth.  EASL Clinical Practice Guidelines: Autoimmune hepatitis. , 2015, Journal of hepatology.

[37]  K. Boberg,et al.  Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. , 1998, Scandinavian journal of gastroenterology.